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Abstract
Background: Left Ventricular Assist Device (LVAD) is a promising therapy for patients with advanced heart failure
(HF), but bleeding complications remain an important issue. Previous series show that acquired von Willebrand
syndrome was present in up to 100 % of first generation LVAD recipients. We report the effects of new generation
LVADs on vW factor (vWF) metabolism and activity in our center.
Methods: Fifteen LVAD recipients (HeartWare®, Framingham, MA, USA) were compared to 12 HF patients, matched
for age and body mass index. vWF antigen and activity, as well as D-dimers, were measured on hemostasis
analyzers. A vWF LVAD-induced alteration was evocated when the [vWF activity]/[vWF antigen] ratio was <0.6.
ADAMTS13 and high molecular weight multimers of vWF were also assessed.
Results: LVAD recipients had similar levels of endothelial vWF production than the HF subjects (137 ± 14.5 vs. 147 ±
11.7 %; respectively, p = 0.611) but a decreased vWF activity (90 ± 11 vs. 132.6 ± 13 %; respectively, p = 0.017). [vWF
activity]/[vWF antigen] ratio was 0.65 ± 0.02 in the LVAD recipients and 0.92 ± 0.06 in the subjects with HF (p = 0.001).
ADAMTS13 activity was 80.3 ± 4.7 % in LVAD recipients and 96.2 ± 3.5 % in the HF patients (p = 0.016). LVAD patients
disclosed markedly elevated D-dimers (3217.7 ± 735 vs. 680.6 ± 223.2 ng/mL FEU in the HF patients, p = 0.006). The
LVAD patients experienced one major hemorrhagic event and one systemic thrombotic event during the median
follow-up of 345 days.
Conclusions: LVAD recipients achieved a new hemostatic equilibrium characterized by infrequent major hemorrhagic
and thrombotic events, despite a mildly impaired vWF function and a markedly enhanced thrombin formation.
Trial registration: ISRCTN39517567
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Background
Patients with advanced heart failure (HF) are often
older than 65 years, have multiple comorbid conditions,
and as a result, are not eligible for heart transplantation
[1]. Should the patient be eligible, then the lengthy
waiting time until transplantation, driven by the limited
organ donor availability, remains unrealistic because of
the poor prognosis of the disease [2]. Left ventricular
assist devices (LVADs) represent a valuable option in
these patients, either as a bridge to transplantation or
as a destination therapy [3]. The early pulsatile devices
performed less well than the newer continuous-flow
pumps, which rely on axial-flow or centrifugal flow
mechanisms [4]. These devices expose the blood com-
ponents to an elevated shear stress and decrease mark-
edly pulse pressure in the arterial blood vessels.
The most frequent adverse event of LVADs is non-
surgical bleeding, especially from the gastro-intestinal
tract during the late follow-up period [5]. Prevalent bleed-
ing episodes in LVAD patients have prompted lower antic-
oagulation targets; however other mechanisms of bleeding
remain a concern. Intestinal hypoperfusion from low pulse
pressure is thought to induce regional hypoxia, subse-
quent vascular dilation, and finally angiodysplasia [5].
* Correspondence: Fatemeh.EsmaeilZadeh@erasme.ulb.ac.be
1Department of Cardiology, Université Libre de Bruxelles (ULB), 808 Lennik
Street, 1070 Brussels, Belgium
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Esmaeilzadeh et al. BMC Cardiovascular Disorders  (2016) 16:155 
DOI 10.1186/s12872-016-0334-z
Acquired von Willebrand syndrome (AvWS) also plays a
role. Vascular endothelial cells express the von Willebrand
factor (vWF) which assembles into multimers. These multi-
mers bind to exposed collagen of damaged blood vessels, as
well as to platelet receptors, resulting in platelet activation,
adhesion, and aggregation [6]. The high molecular weight
multimers of vWF (HMWM-vWF) are the most effective
ones to prevent bleeding [7]. ADAMTS13 (a disintegrin
and metalloproteinase with a thrombospondin type 1 motif,
member 13) cleaves the vWF, under shear stress conditions
in the microcirculation, at a specific site that becomes ac-
cessible when the protein unfolds. vWF conformational
changes, as a result of arterial shear stress, promote vWF
proteolysis by ADAMTS13, and lead to a decrease in multi-
mer size [6]. Cleavage deficiency of vWF (due to a deficit in
ADAMTS13) results in accumulation of superfluous ultra
large molecular weight multimers of vWF (UL-vWF),
which are prothrombotic. This is in contrast to the high
shear stress encountered in the presence of a pulsatile
LVAD or an aortic stenotic valve, which induce an acquired
von Willebrand disease (AvWD), because the conform-
ational changes of the HMWM-vWF resulted in excessive
vWF cleavage and pathological bleedings [8]. Relief of the
abnormal shear stress, as a result of cardiac transplantation
in the LVAD patients, or by surgical and/or percutaneous
aortic valve reopening [9] in the presence of an aortic sten-
osis, can correct this AvWS [8–12]. As such, HMWM-
vWF decreased in patients with LVAD [10, 11], but
returned to normal in 6 patients after heart transplantation,
a finding already reported in an earlier cross-sectional study
[12]. HMWM-vWF levels measured in random fashion in a
variety of advanced HF conditions were mostly normal
[11]. Moreover, in a longitudinal study, LVAD implantation
decreased vWF multimers in all 37 patients [13], while, in a
retrospective study, patients with centrifugal and axial flow
LVADs disclosed comparable reductions in HMWM-vWF
[14]. Finally, there is evidence that LVAD patients disclose
an altered platelet function, which may play a role in the
non-surgical bleedings. This was shown in one study where
11 out of 16 LVAD patients presented an altered ristocetin-
induced platelet aggregation, which normalized in 5 sub-
jects after heart transplantation [10].
The aim of the present study was to characterize
AvWS, platelet function and bleeding events in a small
group of patients implanted with third generation
LVADs at the Erasme Hospital, Brussels, Belgium. These
patients were compared to a group of matched HF patients.
The data presented in this article were collected during a
study on the effects of LVAD on micro-circulatory function
[15]. As such, we have already reported that the vWF anti-
gens did not differ between the LVAD and HF patients
[15]. However no further information was provided on co-




Fifteen LVAD-supported patients were compared, using
a case-control study design, to twelve male HF patients.
Patient’s characteristics of 13 of these LVAD patients,
and of 11 of these HF patients, were already reported in
a previous study [15] . Both groups were matched for
age and body mass index. The study protocol (reference:
P 2013/112) was approved by the Ethical Committee of
the Erasme University Hospital. A written informed con-
sent was obtained from all patients.
Study design
We designed a case-control study. The LVAD patients
who attended the outpatient heart failure clinic were
asked consecutively to participate in the study. Next, the
HF patients who attended the same clinic, and whose
characteristics were similar to those LVAD patients who
had already participated in the study, were enrolled in
the clinical trial. All abstained from meals for 8 h
(except for morning medications) and from alcohol
and coffee beverages for at least 12 h prior to blood
collection. All were asked not to take non-steroidal
anti-inflammatory drugs (NSAIDs) for at least 3 days
before the blood test [15].
Measurements and procedures
Measurements were performed by the hematology
laboratory of the Erasme University Hospital (Brussels,
Belgium), except for the vWF multimers and ADAMTS13
protease activity determinations (Antwerp University Hos-
pital, Antwerp, Belgium and Saint-Luc University Hospital,
Brussels, Belgium, respectively). Twenty-two mL of whole
venous blood samples was collected from each patient and
placed in 4 tubes of 4 mL, with 109 mmol of sodium citrate
(3.2 %), and in 2 tubes of 3 mL with >15 μg/mL of hirudin.
Plasma was separated by centrifugation at 2000 g for
15 min at ambient temperature (20–25 °C). vWF anti-
gen, vWF activity and D-dimers were evaluated by an
immuno-turbidimetric assay, using a fully automated
hemostasis analyzer (BCS XP system, Innovance Siemens®
Healthcare, USA). LVAD-induced vWF alteration was
evocated when the [vWF activity]/[vWF antigen] ratio
was <0.6 [16]. Factor VIII (% activity of normal plasma)
and coagulant fibrinogen (mg/dL) were determined by
chronometric techniques by means of fully automated
hemostasis analyzers (BCS XP system, Siemens® Health-
care, USA; Multifibren U, Siemens® Healthcare, USA; re-
spectively). Prothrombin time (PT, % time of normal
plasma), international normalized ratio (INR), activated
Partial Thromboplastin Time (aPTT, sec) were also
assessed by chronometric techniques. ADAMTS13 activ-
ity was assessed by a chromogenic ELISA method (Tech-
nozym, Technoclone, Austria), based on its activity on a
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synthetic peptide of vWF. The normal range of
ADAMTS13 activity was 40–160 % of healthy subjects
[17]. HMWM-vWF were studied by Western Blot ana-
lysis (GE, Healthcare, Germany), using SDS-agarose gel
electrophoresis. Platelet aggregation was tested at physio-
logical calcium condition by the Multiplate™ analyzer
(Dynabyte, Munich, Germany), using agonists of thrombin
receptor activating peptide-6 (TRAP-6), arachidonic acid
(ASPI), adenosine diphosphate (ADP), a collagen binding
activity assay (COL), and ristocetin. Ristocetin-induced
platelet aggregation was determined at concentrations of
1 mg/mL.
Clinical definition of bleeding and thrombosis
Two types of bleeding were defined prospectively: Minor
bleeding (blood loss without transfusion) and major
bleeding (need for transfusion >7 days after implant-
ation, death after a bleeding, the need for re-operation,
or any transfusion of packed red blood cells 7 days after
implantation). Thrombosis was defined as the formation
of a blood clot within one of the VAD components, or
any systemic thrombo-embolic event. Medical history
was retrieved from the patients’ medical records.
Statistical analysis
All statistical analyses were performed using SPSS (PASW
Statistics 18.0, Chicago, IL, USA). Data are expressed as
mean ± SEM. All data analyses were performed in a
blinded fashion in regard to the presence or absence of a
LVAD. We used one-way analysis of variance (ANOVA)
models, in order to determine the differences in descrip-
tive characteristics and blood measurements among the
study groups. Categorical variables were summarized by
frequencies and percentages, and were analyzed by using
Chi-square tests. Student t tests for independent samples
were used to determine differences in normally distributed
data. Correlation analyses using the Pearson correlation
coefficient were also performed. A p value < 0.05 was con-
sidered statistically significant.
Results
Patients’ characteristics are shown in Table 1 and were
presented elsewhere in detail [15]. An additional dataset
file shows this in more detail (see Additional file 1).
Briefly, all LVAD patients had a HeartWare® Assist
Device (Framingham, MA, USA). Continuous flow cir-
culation was achieved with a pump speed of 2758.7 ±
62.5 rpm and a power of 4.6 ± 0.3 W. The follow up
period during which events were assessed was 345 ±
63 days. The LVAD and HF groups did not differ in age,
body mass index, race, history duration of heart failure
and HF etiology. The LVAD group disclosed a lower pro-
portion of men (p = 0.013 vs. HF patients) and was less
frequently treated with angiotensin converting enzyme
inhibitors or angiotensin receptor blockers (p = 0.030 vs.
HF patients). LVAD patients received more frequently oral
anticoagulant therapy (p = 0.001 vs. HF patients). Anti-
platelet therapy prevalence did not differ, as well as the
prevalence of other treatments, between both groups. Co-
morbidities were also similar [15].
Effect of LVAD on vWF profile and other blood
components (Table 2, Additional file 1, Fig. 1)
Plasma vWF antigen in LVAD patients did not differ
from the HF patients (p = 0.611). On the contrary, vWF
activity was lower in the LVAD group, in comparison to
the HF patients (p = 0.017). As a result, the [vWF activ-
ity]/[vWF antigen] ratio was reduced in the LVAD pa-
tients (p = 0.001 vs. HF patients). The vWF antigen and
vWF activity in LVAD patients with blood group “O”
did not differ from the other blood groups. ADAMTS13
activity was decreased in LVAD patients (p = 0.016). Factor
VIII activity, fibrinogen levels, platelet count, as well as
Table 1 Patients’ characteristics
Parameters LVAD (n = 15) HF (n = 12) p
Age (Y) 43 ± 4 47.2 ± 2.4 0.389
Men (%) 60 100 0.013
BMI (Kg/m2) 25.6 ± 1.2 29.1 ± 1.6 0.085
Race (caucasian) 14 12 0.362
Month with HF 51.3 ± 15 62 ± 20 0.665
Nonischemic HF etiology (%) 93 75 0.183
NYHA class 2.1 ± 0.1 2.2 ± 0.1 0.229
LVEF (%) 24 ± 2.6 27 ± 2.5 0.540
Heart rate (bpm) 88 ± 5 72 ± 4.6 0.030
Mean BP (mm Hg) 104 ± 11 91 ± 3.7 0.292
Medications (%)
ß-blockers 80 100 0.100
ACE/ARB 53.3 91.7 0.030
Diuretic 80 75 0.756
Digitalic 6.7 8.3 0.869
Long acting nitrate 6.7 8.3 0.869
Statine 33.3 50 0.381
Antiarrhythmic 40 33.3 0.722
Oral anticoagulant 100 41.7 0.001
Anti-platelet therapy 66.7 50 0.381
Underlying diseases (%)
Hypertension 6.7 41.7 0.030
Diabetes 20 16.7 0.825
Chronic renal failure 26.7 16.7 0.535
Smoker 46.7 50 0.863
BMI body mass index, NYHA New York Heart Association, LVEF left ventricular
ejection fraction, BP blood pressure, ACE/ARB angiotensin converting enzyme/
angiotensin receptor blocker; Diabetes (Fasting blood glucose > 126 mg/dL or
antidiabetic medications); Chronic renal failure (Creatinine >2.0 mg/dL)
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the prevalence of the “O” blood group, did not differ
between the patients with or without LVADs. LVAD
patients disclosed five-fold higher D-dimers levels (p =
0.006 vs. HF patients), higher INR and aPTT (all p = 0.001
vs. HF patients), while their PT was reduced (p = 0.001 vs.
HF patients). Platelet aggregation tests in LVAD patients
disclosed preserved spontaneous responses, as well as to
ADP, while the responses to 1 mg/mL ristocetin, to agonists
of TRAP-6, to ASPI and to COL were diminished (p =
0.019, 0.028, 0.024 and 0.012 respectively vs. HF patients).
Clinical events in the LVAD patients (Additional file 1)
The LVAD recipients experienced 1 major and 4 minor
bleedings during the follow-up period. One patient dis-
closed a spontaneous rupture of a hemangioma in the
inferior pole of spleen 93 days after LVAD implantation.
He received 2 packed cell units and 4 units of fresh fro-
zen plasma (FFP). This event occurred 65 days prior par-
ticipation to this study. The 4 minor bleeds consisted in
3 transient nose bleedings and 1 hemorrhoid bleeding.
These 4 LVAD patients disclosed similar vWF antigen,
vWF activity and [vWF activity]/[vWF antigen] ratios than
those who did not experience bleeding events. The patient
with a major hemorrhage presented also a clinical cere-
brovascular event, unnoticeable at the brain computed
tomography.
Discussion
This study explores the effects of new generation LVADs
on vWF function in patients followed in a Belgian aca-
demic centre. The main findings of our study are that
our LVAD recipients presented a mild reduction in vWF
activity, as compared to matched HF patients. This is
consistent with previous studies in LVAD-assisted pa-
tients where vWF activity was only relatively reduced
[13]. Plasma vWF antigen in LVAD patients did not dif-
fer from the HF patients, indicating similar endothelial
vWF production in both groups [15]. The [vWF activ-
ity]/[vWF antigen] ratios were, on average, just above
the lower limit of normalcy in the LVAD recipients, but
Table 2 Blood test data
Parameters LVAD (n = 15) HF (n = 12) Normal range p
vWF antigen (IU/dL) 137 ± 14.5 147 ± 11.7 50–200 0.611
vWF activity (IU/dL) 90 ± 11 132.6 ± 13 50–200 0.017
[vWF activity]/[vWF antigen] ratio 0.65 ± 0.02 0.92 ± 0.06 >0.60 0.001
ADAMTS13 (%) 80.3 ± 4.7 96.2 ± 3.5 >40 0.016
Factor VIII (%) 173 ± 16 167.4 ± 16 55–205 0.813
Fibrinogen (mg/dL) 408.4 ± 23.4 371 ± 23.2 160–400 0.272
D-dimers (ng/mL FEU) 3217.7 ± 735 680.6 ± 223.2 <500 0.006
vWF multimer deficit levels 3/15 1/12 NA 0.396
Blood group “O” (% of patients) 33 41 NA 0.683
Platelet count (109/L) 237 ± 25 207 ± 20 150–450 0.373
INR 2.6 ± 0.2 1.4 ± 0.2 0.8–1.2 0.001
aPTT (sec) 34.4 ± 1.2 26.5 ± 1.3 24–35 0.001
PT (%) 28.8 ± 3.5 78.2 ± 9.8 70–130 % 0.001
CRP 14.1 ± 3.8 6.45 ± 2 <10 0.108
Bilirubin total 0.58 ± 0.07 0.68 ± 0.1 <1.2 0.448
Alkaline Phosphatase 95.3 ± 15.2 77.7 ± 11.6 56–119 0.383
ALT (SGPT) 23.3 ± 3.85 56 ± 21.8 <45 0.113
AST (SGOT) 21.4 ± 1.35 47.4 ± 19.4 <35 0.146
Multiplate analysis
Ristocetin 1 mg/mL (U) 61 ± 8.2 92.6 ± 9.7 90–201 0.019
Adenosine diphosphate (U) 62.3 ± 6.3 73.7 ± 8.7 53–122 0.285
Thrombin receptor activating peptide-6 (U) 93.7 ± 5.6 113.8 ± 6.5 94–156 0.028
Arachidonic acid (U) 33.1 ± 7.6 60.7 ± 8.5 75–136 0.024
Collagen binding activity assay (U) 43.1 ± 4.6 62.8 ± 5.8 46–117 0.012
Spontaneous (U) 10 ± 2.3 14.3 ± 2.5 1–25 0.226
INR international normalized ratio, aPTT activated partial thromboplastin time, PT prothrombin time, CRP C-Reactive Protein, ALT alanine aminotransferase, AST
aspartate aminotransferase, NA not applicable
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were close to 1 in the HF patients. The fact that this
ratio was lower in LVAD patients is likely due to a re-
duction in the HMWM. LVAD patients also disclosed
five-fold elevated D-dimers levels [18], as compared to
the matched HF patients, revealing a markedly en-
hanced thrombin formation, with subsequent risk for
platelet activation and thrombotic events. This is why
antiplatelet and anticoagulant therapies are recom-
mended in LVAD patients [19]. The use of vitamin K
antagonists may also indirectly influence platelet func-
tion through thrombin formation inhibition. The lower
responses to TRAP-6 agonists, ASPI and COL in the
LVAD recipients are most likely explained by their
anti-platelet medications. However, our LVAD patients
presented an altered ristocetin-induced platelet aggre-
gation, also observed in a previous study [10]. These
results might indicate that ristocetin-induced platelet
aggregation is sensitive to the HMWM-vWF, since
this cannot be explained by the medications taken by
LVAD patients. Major hemorrhagic events were
nevertheless seldom and one thrombotic event oc-
curred during the follow-up period. Thus, our LVAD
recipients were capable to achieve a remarkable new
hemostatic equilibrium despite the several novel pro-
hemorrhagic (such as a reduced vWF activity, antivitamin
K and anti-platelet therapy) and pro-thrombotic (en-
hanced D-dimers formation) factors elicited by the assist-
ance therapy.
HMWM-vWF and ADAMTS13
The vWF antigens did not differ between the LVAD re-
cipients and the matched HF patients. Factor VIII level,
which enhances vWF proteolysis by ADAMTS13 under
fluid shear stress [20], but not under static conditions,
did also not differ between the LVAD and HF patients.
Therefore, reductions in endothelial production of vWF
and factor VIII imbalance cannot explain the mild re-
duction in vWF activity we observed. High shear stress,
which presumably unfolds the central A2 domain of
ultra large plasmatic vWF, restores the sensitivity of
vWF to ADAMTS13 [21]. Pump-induced shear stress in
LVAD patients might therefore enhance HMWM-vWF
breakdown into smaller units, leading to lower vWF
activity [22]. Elevated HMWM-vWF cleavage consumes
ADAMTS13 during its action on vWF [22]. As a
result, both vWF activity and ADAMTS13 levels de-
crease [22, 23]. This is in contrast to our HF patients,
whose normal [vWF activity]/[vWF antigen] ratios were
also accompanied by normal ADAMTS13 levels. Others
mechanisms might nevertheless contribute to the differ-
ences in ADAMTS13 levels we observed. ADAMTS13 is
predominantly synthetized in hepatic stellate cells and dif-
fuses subsequently into capillaries and the blood stream
[21]. ADAMTS13 is markedly upregulated when activated
by inflammatory cytokines, such as transforming growth
factor-β [24]. Moreover, experimental cholestasis and stea-
tohepatitis elevate plasma ADAMTS13 levels [25], while
Fig. 1 Individual measures of vWF activity (IU/dL), [vWF activity]/[vWF antigen] ratio, ADAMTS13 (%), D-dimers (ng/mL FEU) in the LVAD patients
(open lozenges) and HF patients (closed circles) and their respective mean ± SEM values. *: p < 0.05, +: p = 0.001, number of measures seem less
than actual because of overlapping individual values
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partial hepatectomy in humans has the opposite effect
[26]. Although not significant, alanine aminotransferase
and aspartate aminotransferase were lower in the LVAD
patients than in the HF patients (Table 2, Additional file
1). We cannot rule out that improved hepatic function in
the LVAD patient, as compared to the non-assisted HF
patients, play a role in our observations.
Clinical events in the LVAD patients
Several studies demonstrated earlier times to first bleed-
ing with HeartMate II (i.e. 33 days [27], 40 days [28] and
176 days after implantation [29]) as compared to the
HeartWare, where the mean time to the first bleeding
was 273 days [30] and 86 % of these events occurred
30 days after implantation [30]. Gastro-intestinal bleed-
ings were reported in nearly 15.4 % of the patients sup-
ported with HeartWare [30]. In our study, the time to
the first bleeding was 93 days after implantation for
major bleeding, and 254 days for the minor bleedings,
with a range of 87–505 days. These bleedings were not
more prevalent in those assisted for a longer time. In
previous studies [14, 31, 32], patients at higher centrifu-
gal speeds demonstrated a lower percentage of HMWM-
vWF and, as a result, a higher frequency of bleeding.
Thus to minimize bleeding events, the LVAD speed
should be the lowest possible [33, 34]. This is because
low speed HeartWare therapy lessens shear stress, re-
duces vWF molecule unfolding and reduces ADAMTS13
accessibility to the vWF multimers. In our study, the
speed of the LVAD devices in the 3 patients with low
HMW-multimers was on average 218 rpm higher than
in the other patients (p = 0.170). Nevertheless, with the
low pump speeds used in our patients, bleedings were
scarce despite all LVAD patients received concomitant
anticoagulation therapy to prevent thrombo-embolic
events. The fact that [vWF activity]/[vWF antigen] ratios
remained on average just above the lower limit of nor-
malcy in our study, may have limited the risk of bleedings
in our LVAD recipients. Other studies have however
shown poor relation between gastrointestinal bleedings
and vWF activity [35]. This is perhaps because they did
also not perform coagulation analysis at the time of bleed-
ing. In mitigation, however, it should be remembered that
the assessment of coagulation in such acute circumstances
has also limitations and pitfalls [36].
Another limitation of our study is that we did not
assess the vWF profiles before LVAD implantation. As a
consequence, we cannot exclude a pre-existing AvWS
prior to LVAD implantation. This was also the case in
several previous publications on this topic [11, 37]. In
most recent longitudinal studies, AvWS occurred in all
patients after axial or centrifugal LVAD, as demonstrated
Fig. 2 vWF multimer analysis in a low resolution gel (1.2 % SDS-agarose). The large multimers are found in the upper part of the gel. Results
obtained from normal pooled plasma are compared to those from the LVAD recipients with an AvWS (presented in the Discussion section) and
a HF patient with normal vWF multimers
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by a 34 % reduction in HMWM-vWF [14]. There are
reasons to believe that only one of our LVAD recipients
disclosed a true AvWS. This patient had a reduced [vWF
activity]/[vWF antigen] ratio of 0.44, an abnormal multi-
mer distribution (Fig. 2) and a minor bleeding episode.
His relative lower vWF activity could be due to the
LVAD. However, without pre-implantation data, we can-
not ascertain whether this patient had an inherited or an
acquired vWS.
Four additional patients disclosed some features of a
vWS. Two of these patients displayed lower HMW-
multimer levels in favour of an AvWS. An inflammatory-
related rise in their vWF could explain why they were
nevertheless capable to maintain a normal vWF activity
and did not disclose bleedings. Type 1 vWS is character-
ized by low levels of normally functioning vWF. This was
observed in 2 patient who showed low levels of vWF
activity (eventually related to blood group “O” in one, but
the second one had a blood group “A”), their [vWF activ-
ity]/[vWF antigen] ratio were respectively 0.62 and 0.64
with normal multimer distribution, however they did not
present bleedings.
Limitations
In addition to the limitations already mentioned, our study
has also several other pitfalls which need to be under-
scored, namely the small sample size of the two group of
patients, the cross-sectional design of our study and the
fact that the patients with LVAD could not be matched to
the HF patients for gender, and inevitably, for all medica-
tion classes. Moreover, we did not characterize changes
within the different vWF size ranges in our study.
Conclusion
The recipients investigated in our study achieved a re-
markable new hemostatic equilibrium despite the many
novel pro-hemorrhagic and pro-thrombotic factors elic-
ited by their LVADs. Major hemorrhagic events were
seldom, and one thrombotic event occurred during the
follow-up period.
Additional file
Additional file 1: LVAD data. This file contains individual characteristics
and blood tests data of the both LVAD and HF patients. (XLSX 57 kb)
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